Pfizer Deal Will Dramatically Reshape Mylan’s Model
Executive Summary
Following the announcement of a merger between Mylan and Pfizer’s Upjohn, the top executive team that will take charge of the combination has set out its vision for the company.
You may also be interested in...
Viatris Share Price Plunges Amid Weak 2021 Financial Guidance
Viatris’ share price closed the day nearly 15% down after announcing weaker than anticipated revenue, adjusted EBITDA and cash flow guidance for 2021. The market reacted strongly to the company’s expectations and ambitions, with management continuing to stress the strength of the combined Mylan and Upjohn businesses.
Who’s Hired? ANI Names New CEO
ANI Pharmaceuticals has chosen its new president and CEO to replace interim chief Patrick Walsh who stepped in after the departure Arthur Przybyl earlier this year. Meanwhile, key personnel announcements have also been made by Teva and Mylan.
Mylan Delays Restructuring Amid COVID-19
Mylan has delayed a major restructuring program ahead of its planned merger with Pfizer’s Upjohn unit due to the impact of the COVID-19 pandemic, which at the same time brought tailwinds for the firm’s first-quarter results.